drugset / Trial / NCT06401824
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Timeline
- Start
- 2025-04-24
- Primary completion
- 2026-11-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |